{"entity":{"id":"nct07518329","kind":"trial","name":"Study of ALA-101 in Patients With CD19 Positive Non-Hodgkin Lymphoma and Leukemia.","aka":[],"tldr":"A phase 1 trial of ALA-101 run by Arovella Therapeutics Ltd, now recruiting.","summary":"Study of ALA-101 in Patients With CD19 Positive Non-Hodgkin Lymphoma and Leukemia. is a phase 1 interventional study registered as NCT07518329 by Arovella Therapeutics Ltd, with 46 participants planned, started 2026-10-19. Conditions recorded: Non Hodgkin Lymphoma (NHL) and Leukaemia. Interventions recorded: ALA-101.","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT07518329","url":"https://clinicaltrials.gov/study/NCT07518329"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["non-hodgkin-lymphoma","leukaemia"],"sections":[],"technologies":[],"targets":[],"drugs":["ala-101"],"companies":["arovella-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07518329","phase":"1","setting":"A Phase 1 Open-Label Dose-Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ALA-101, Allogeneic, Off-the-shelf, CD19-directed CAR-iNKT Cells in Patients With CD19+ Non-Hodgkin Lymphoma and Leukemia","sponsor":"Arovella Therapeutics Ltd","enrolled":46,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07518329/","neighbours":{"cancer":[{"id":"leukaemia","kind":"cancer","name":"Leukaemia (all types)","route":"/cancers/leukaemia/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"drug":[{"id":"ala-101","kind":"drug","name":"ALA-101","route":"/drugs/ala-101/"}],"company":[{"id":"arovella-therapeutics","kind":"company","name":"Arovella Therapeutics","route":"/companies/arovella-therapeutics/"}]}}